Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Erimos Pharmaceuticals
Collaborators
NCT07550010 · Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2), and more
NCT04712851 · Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, and more
NCT07275333 · Cervical Cancer, Cervical Cancer Screening, and more
NCT06403618 · Cervical Intraepithelial Neoplasia Grade 2
NCT05266898 · Papillomavirus Vaccines, Human Immunodeficiency Virus, and more
University of Maryland, Dept. of Family Medicine
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions